Sarepta Therapeutics is proud to announce a significant milestone in our journey: the successful raising of $600,000,000 in funding. Headquartered in Cambridge, Massachusetts, our global biotechnology company is dedicated to engineering precision genetic medicine for rare diseases that devastate lives and cut futures short. This new capital infusion will accelerate our research and development initiatives across our expansive portfolio, which includes leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), as well as over 40 promising programs in various stages of development. The funds will be strategically deployed to bolster our multi-platform Precision Genetic Medicine Engine, enhancing our gene therapy, RNA, and gene editing capabilities to bring transformative treatments to patients in need.
In this pivotal phase, we plan to strengthen our infrastructure, invest in innovative clinical research, and deepen collaborative efforts with academic and industry partners. Our commitment to transparency and ethical practices remains unwavering; we invite our stakeholders to learn more about our community guidelines at sarepta.com/community-guidelines. Additionally, as we continue to grow and attract talent, we encourage job seekers to remain vigilant against recruiting fraud and to refer to the dedicated safeguards and steps outlined on our website. This funding milestone not only reaffirms the confidence that investors have in our cutting-edge scientific mission but also reinforces our resolve to drive breakthrough discoveries that redefine the standard of care for rare genetic diseases. We are excited about the future and remain committed to improving patients’ lives, ensuring hope and renewed possibilities through precision genetic medicine.
